BR112022020807A2 - Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3 - Google Patents
Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3Info
- Publication number
- BR112022020807A2 BR112022020807A2 BR112022020807A BR112022020807A BR112022020807A2 BR 112022020807 A2 BR112022020807 A2 BR 112022020807A2 BR 112022020807 A BR112022020807 A BR 112022020807A BR 112022020807 A BR112022020807 A BR 112022020807A BR 112022020807 A2 BR112022020807 A2 BR 112022020807A2
- Authority
- BR
- Brazil
- Prior art keywords
- inhibitors
- triazine
- pathway
- acetamides
- pyrazole
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102000000874 Pyrin Domain-Containing 3 Protein NLR Family Human genes 0.000 title abstract 2
- 108010001946 Pyrin Domain-Containing 3 Protein NLR Family Proteins 0.000 title abstract 2
- 230000037361 pathway Effects 0.000 title abstract 2
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 108091008099 NLRP3 inflammasome Proteins 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- HQOWKLMFRPLHHW-UHFFFAOYSA-N NC(CN1N=CN2N=CC=C2C1)=O Chemical compound NC(CN1N=CN2N=CC=C2C1)=O HQOWKLMFRPLHHW-UHFFFAOYSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
PIRAZOLO[1,5-D][1,2,4]TRIAZINA-5(4H)- ACETAMIDAS COMO INIBIDORES DA TRAJETÓRIA DE INFLAMASSOMA DE NLRP3. A presente invenção refere-se a compostos inovadores para uso como inibidores da produção de inflamassoma de NLRP3, em que tais compostos são como definido pelos compostos da fórmula (I) e em que os números inteiros R1, R2 e R3 são definidos na descrição, e em que os compostos podem ser úteis como medicamentos, por exemplo, para uso no tratamento de uma doença ou transtorno que é associado à atividade de inflamassoma de NLRP3.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382297 | 2020-04-15 | ||
| PCT/EP2021/059789 WO2021209552A1 (en) | 2020-04-15 | 2021-04-15 | Pyrazolo[1,5-d][1,2,4]triazine-5(4h)-acetamides as inhibitors of the nlrp3 inflammasome pathway |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020807A2 true BR112022020807A2 (pt) | 2022-11-29 |
Family
ID=70391032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020807A BR112022020807A2 (pt) | 2020-04-15 | 2021-04-15 | Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230203044A1 (pt) |
| EP (1) | EP4135843A1 (pt) |
| JP (1) | JP2023522016A (pt) |
| KR (1) | KR20230002676A (pt) |
| CN (1) | CN115427110A (pt) |
| AU (1) | AU2021257619A1 (pt) |
| BR (1) | BR112022020807A2 (pt) |
| CA (1) | CA3174837A1 (pt) |
| MX (1) | MX2022012897A (pt) |
| WO (1) | WO2021209552A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2023550153A (ja) * | 2020-11-23 | 2023-11-30 | エフ． ホフマン－ラ ロシュ アーゲー | Ｂ型肝炎ウイルス感染症の処置および予防のためのｎ－［（１，３－ベンゾオキサゾル－２－イル）－複素環］アミド誘導体 |
| CN114031619A (zh) * | 2021-12-17 | 2022-02-11 | 山东汇海医药化工有限公司 | 一种图卡替尼中间体的制备方法 |
| WO2023118521A1 (en) | 2021-12-22 | 2023-06-29 | Ac Immune Sa | Dihydro-oxazol derivative compounds |
| WO2023159148A2 (en) * | 2022-02-18 | 2023-08-24 | Ptc Therapeutics, Inc. | Inhibitors of nlrp3 |
| WO2023232917A1 (en) * | 2022-06-03 | 2023-12-07 | F. Hoffmann-La Roche Ag | Novel compounds |
| WO2024013395A1 (en) | 2022-07-14 | 2024-01-18 | Ac Immune Sa | Pyrrolotriazine and imidazotriazine derivatives as modulators of the nlrp3 inflammasome pathway |
| US20240101563A1 (en) | 2022-07-28 | 2024-03-28 | Ac Immune Sa | Novel compounds |
| WO2024064245A1 (en) | 2022-09-23 | 2024-03-28 | Merck Sharp & Dohme Llc | Phthalazine derivatives useful as inhibitors of nod-like receptor protein 3 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB862825A (en) * | 1957-02-06 | 1961-03-15 | Ilford Ltd | Improvements in or relating to cyanine and merocyanine dyes |
| US11718631B2 (en) | 2017-10-17 | 2023-08-08 | Novartis Ag | Sulphonamides and compositions thereof for treating conditions associated with NLRP activity |
| GB201721185D0 (en) | 2017-12-18 | 2018-01-31 | Nodthera Ltd | Sulphonyl urea derivatives |
| GB201803393D0 (en) | 2018-03-02 | 2018-04-18 | Inflazome Ltd | Novel compounds |
| EP3817817A1 (en) | 2018-07-03 | 2021-05-12 | Novartis AG | Nlrp modulators |
| JP7320595B2 (ja) | 2018-07-20 | 2023-08-03 | エフ． ホフマン－ラ ロシュ アーゲー | インターロイキン－１活性の阻害剤としてのスルホンイミドアミド化合物 |
| MA53388A (fr) | 2018-07-25 | 2021-06-02 | Novartis Ag | Inhibiteurs d'inflammasome nlrp3 |
| WO2020037116A1 (en) | 2018-08-17 | 2020-02-20 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Small molecule pyrin-domain targeted nlrp3 inflammasome inhibitors |
-
2021
- 2021-04-15 BR BR112022020807A patent/BR112022020807A2/pt unknown
- 2021-04-15 CA CA3174837A patent/CA3174837A1/en active Pending
- 2021-04-15 AU AU2021257619A patent/AU2021257619A1/en active Pending
- 2021-04-15 JP JP2022562620A patent/JP2023522016A/ja active Pending
- 2021-04-15 EP EP21719126.1A patent/EP4135843A1/en active Pending
- 2021-04-15 US US17/996,090 patent/US20230203044A1/en active Pending
- 2021-04-15 KR KR1020227039560A patent/KR20230002676A/ko active Search and Examination
- 2021-04-15 CN CN202180028683.XA patent/CN115427110A/zh active Pending
- 2021-04-15 MX MX2022012897A patent/MX2022012897A/es unknown
- 2021-04-15 WO PCT/EP2021/059789 patent/WO2021209552A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4135843A1 (en) | 2023-02-22 |
| MX2022012897A (es) | 2022-11-14 |
| JP2023522016A (ja) | 2023-05-26 |
| CN115427110A (zh) | 2022-12-02 |
| US20230203044A1 (en) | 2023-06-29 |
| WO2021209552A1 (en) | 2021-10-21 |
| CA3174837A1 (en) | 2021-10-21 |
| KR20230002676A (ko) | 2023-01-05 |
| AU2021257619A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020807A2 (pt) | Pirazolo[1,5-d][1,2,4]triazina-5(4h)-acetamidas como inibidores da trajetória de inflamassoma de nlrp3 | |
| BR112022023271A2 (pt) | Compostos | |
| BR112022020776A2 (pt) | Pirrolo[1,2-d][1,2,4]triazina-2-il-acetamidas como inibidores da via do inflamassoma de nlrp3 | |
| BR112022020798A2 (pt) | Compostos tricíclicos como inibidores de nlrp3 | |
| BR112022021881A2 (pt) | Novos compostos de triazinoindol | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| BRPI0513086A (pt) | 8-pirrolidinoxantinas bicìclicas substituìdas, processo para a produção das mesmas e seu uso como medicamentos | |
| ECSP22087539A (es) | Inhibidores de kras tricíclicos fusionados | |
| BR112013020605A2 (pt) | derivados de 6-ciclobutil-1,5-diidro-pirazol[3,4-d]pirimidin-4-ona e seu uso como inibidores de pde9a | |
| BR112013021638A2 (pt) | "compostos inibidores de trk, seu uso e composições que os compreendem" | |
| BRPI0607927A2 (pt) | derivados de pirazol-pirimidina | |
| BRPI0514692A (pt) | inibidores do receptor sigma | |
| BR112013003097A2 (pt) | 6-cicloalquil-pirazolopirimidemonas para o tratamento de distúrbio de cns | |
| ECSP088322A (es) | Derivados de fenil-1,2,4-oxadiazolona, procesos para su preparación y su uso como compuestos farmacéuticos | |
| BR112017018643A2 (pt) | "derivados de tetra-hidrotiazepina bicíclicos úteis, composição farmacêutica compreendendo os mesmos, seu uso, e método in vitro ou ex vivo para a produção de células imunes ativadas" | |
| BR112022021514A2 (pt) | [1,3]diazino[5,4-d]pirimidinas como inibidores de her2 | |
| BR112023019030A2 (pt) | Derivados de fósforo como inibidores de sos1 | |
| BR112019006023A2 (pt) | forma cristalina, métodos de preparação da forma cristalina e do composto, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou enfermidade e para modular atividade de cinase. | |
| BRPI0510514A (pt) | beta-agonistas, processos para a sua produção e seu uso como medicamento | |
| BRPI0614831A2 (pt) | antagonistas de cgrp selecionados, processo para sua produção bem como seu uso como medicamentos | |
| BR112021026820A2 (pt) | Inibidores heterocíclicos de monoacilglicerol lipase (magl) | |
| BR112022023983A2 (pt) | Compostos terapêuticos | |
| BR112022016131A2 (pt) | Compostos para tratamento de infecção por coronavírus | |
| MX2023003459A (es) | Nuevos compuestos. | |
| BR112023005214A2 (pt) | Compostos inovadores |